Welcome to our dedicated page for Hercules Capital news (Ticker: HTGC), a resource for investors and traders seeking the latest updates and insights on Hercules Capital stock.
Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, venture capital-backed and institutional-backed companies, with an emphasis on technology and life sciences industries. Its updates commonly address debt and equity commitments, loan fundings, portfolio-company financings, net investment income, net asset value, leverage, available liquidity and recurring cash distributions.
Hercules also reports developments involving credit ratings, annual meeting and proxy matters, executive leadership, and its asset management activity through Hercules Adviser LLC and related Adviser Funds. The company’s common stock trades on the NYSE under HTGC, and its retail notes trade under HCXY.
Compass Pathways (Nasdaq: CMPS) announced the U.S. FDA has accepted its IND for COMP360 in PTSD, enabling initiation of a Phase 2b/3 (COMP202) trial with a 12-week blinded Part A and 40-week open-label Part B; the primary endpoint is change in CAPS-5 at Week 8. Compass said prior Phase 2 open-label PTSD data showed rapid, durable symptom improvement (published September 2025). The company also reviewed commercial readiness for COMP360 in TRD and disclosed planned data timing: second half of Q1 2026 for combined COMP006/COMP005 readouts and COMP006 Part B 26-week data expected early Q3 2026. Financially, Compass amended a Hercules loan to up to $150M with $50M drawn, extended interest-only through at least January 5, 2029, and extended maturity to January 5, 2031.
Hercules Capital (NYSE: HCXY) said members of its executive management team will participate in the Citizens Financial Services Conference in New York on Tuesday, November 18, 2025.
Management availability includes participation in the conference and one-on-one meetings, which can be arranged through Citizens Financial Services.
Hercules Capital (NYSE: HTGC) reported record third-quarter and year‑to‑date activity for 2025, with Q3 total debt and equity commitments of $846.2M and record Q3 fundings of $504.6M. Year‑to‑date through Q3, commitments reached $2.87B and fundings $1.75B. Q3 investment income was $138.1M and Q3 net investment income (NII) was $88.6M or $0.49 per share, covering 122% of the base cash distribution.
Balance-sheet highlights: net GAAP leverage 98.2%, net regulatory leverage 82.3%, over $1.0B of available liquidity, undistributed earnings spillover of $146.2M ($0.80 per ending share), approximately $5.5B AUM (+20.7% YoY), and a Moody’s upgrade to Baa2.
Hercules Capital (NYSE:HCXY) declared a $0.47 per share total cash distribution for Q3 2025, composed of a $0.40 base distribution and a $0.07 supplemental distribution. The record date is November 12, 2025 and the payment date is November 19, 2025.
The Board maintains a variable distribution policy targeting distributions that approximate 90%–100% of taxable quarterly income and may pay supplemental amounts to distribute annual taxable income in the year earned. Of distributions declared for the quarter ended September 30, 2025, 100% were derived from current earnings and profits. Year-to-date Qualified Interest Income (QII) for 2025 distributions is 79.05%.
Hercules Capital (NYSE: HCXY) announced it reached $25.0 billion in total cumulative debt commitments since its first origination in October 2004, as of October 27, 2025. The company reported a 21-year 41.5% compound annual growth rate in cumulative commitments and highlighted key scale metrics including ~5.5 billion in assets under management (AUM) as of September 30, 2025, more than 700 portfolio companies, >1,000 venture/private equity sponsors, and over 270 IPO or M&A liquidity events.
The announcement credits its investment team, underwriting discipline, and partnerships for the milestone.
Hercules Capital (NYSE: HTGC) will release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. The company will host a conference call the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Investors can join via telephone or live webcast at the Investor Resources section of investor.htgc.com. Domestic dial-in: +1 (800) 267-6316. International dial-in: +1 (203) 518-9783. Callers should dial in 10–15 minutes early and reference conference ID HTGCQ325. An archived replay will be available on the same investor webpage.
Tipalti, a finance automation platform, has secured $200 million in growth financing from Hercules Capital (NYSE: HTGC). The funding will support AI development and global expansion. The company has unveiled enhanced Tipalti AI with new AI agents, including Reporting, Tax Form Scan, Purchase Request, and Branded Experience agents.
The company reported significant growth metrics, including reaching $200 million in annual recurring revenue (ARR), 30% year-over-year customer base growth, and processing payments at a $75 billion annualized payment volume (30% YoY increase). Tipalti now serves over 5,000 global companies across multiple regions including the U.S., Canada, UK, and EU.
Hercules Capital (NYSE:HTGC), the largest specialty financing provider to venture and growth companies, has received a significant credit rating upgrade from Moody's Investors Service. The company's investment grade credit and corporate rating has been upgraded to Baa2 with a revised outlook to stable.
The upgrade is attributed to Hercules' 22-year strong operating history as a business development company (BDC), demonstrating robust profitability and asset quality performance. Key factors include the company's low leverage, minimal reliance on secured funding sources, and strong equity market access, supported by its internally managed structure.
Hercules Capital (NYSE:HTGC), the largest specialty financing provider to venture-backed companies, has received an affirmed BBB+ investment grade rating from Kroll Bond Rating Agency (KBRA). The rating affirmation reflects HTGC's strong market position in venture debt, particularly in technology and life sciences sectors.
KBRA's positive assessment highlights Hercules' 20+ year operating track record, robust risk management, diversified investment portfolio focused on senior secured first lien debt, and solid capital market access. The stable outlook is supported by appropriate leverage metrics and a high proportion of unsecured debt providing strong noteholder protection.
Heron Therapeutics (NASDAQ: HRTX) has completed a comprehensive capital restructuring to enhance financial flexibility and reduce debt. The multi-faceted refinancing includes: a $110 million senior credit facility from Hercules Capital (with additional $40 million available in milestone-based tranches), retirement of existing convertible notes through $125 million cash repayment and $25 million stock conversion, issuance of $35 million new convertible notes, and a $27.7 million private placement.
The restructuring aims to eliminate near-term debt maturities and provide working capital for commercial and development initiatives. The transactions, initiated on August 8, 2025, are expected to close on August 12, 2025.